MediumV Technology Geopolitics & AI5 October 2026, Monday
Qualcomm agrees to buy Huawei's US patents, pending Washington's approval
Huawei and Qualcomm announced on 5 October a multi-year cross-licence agreement covering 5G, computing, AI and networking technologies. Qualcomm will also acquire some of Huawei's US patents; the transaction is subject to regulatory approval.
According to Huawei's statement from Shenzhen on 5 October, the agreement cross-licenses the two companies' patent portfolios. A cross-licence allows each party to use the other's patents without the risk of litigation. Neither company disclosed the financial terms on 5 October. TechSpot said this is the first licence between the two to cover 5G; Huawei made its first licence payment to Qualcomm in 2001.
The critical detail is the change of direction. For 25 years Huawei was the party paying licence fees; now Qualcomm is buying its US-registered patents. Huawei has been on the US Commerce Department's Entity List since 2019, which makes any transfer of US technology to a listed company subject to a licence. Export controls target the flow of technology, not the flow of payments. As of 5 October it was therefore unclear which agency would have to approve the deal. Huawei said the agreement takes the cumulative value of its licensing deals to about $7bn; the company held more than 165,000 valid patents at the end of 2025.
The timing also matters. US Treasury Secretary Scott Bessent announced in late September that the US–China trade truce had been extended from 10 November to 10 January 2027, as both sides seek a bigger deal. The approval process will show how Washington, under restrictions in place since 2019, views the purchase of intellectual property from a Chinese company on its sanctions list.
Talay assessment
Bottom line
The deal shows technology decoupling running in reverse at the intellectual property layer. Huawei is no longer just a licensee but a seller of patents to a US rival. Approval will very probably come during the truce. But a payment to a sanctioned company will give fresh material to the chip-control debate in Congress.
Likely effects
- Standard-essential patentsUncertain6 months+
Growth in Huawei's 5G licensing income turns China's weight in international standard-setting into a revenue stream; the royalty base Western device makers pay to Huawei could widen.
- US export controlsNegative1–6 months
Because a patent purchase creates a flow of money rather than technology, it may slip past existing rules; that gap could fuel proposals in Congress to curb dealings with Entity List firms.
- US–China trade talksPositiveWeeks
A deal approved during the truce, now extended to 10 January 2027, would be concrete evidence that both sides want to keep commercial channels open.
Possibilities, ranked
- 1Approval granted60%
Regulators approve the deal during the truce; the patent transfer completes and the financial terms stay confidential.
Watch: A closing notice for the deal in Qualcomm's quarterly report
- 2Approval drags on30%
Objections from Congress prolong the review, and the deal does not close before the truce expires on 10 January 2027.
Watch: A letter from senators to the Commerce Department about the deal
- 3Deal blocked10%
The US administration halts the patent purchase on national security grounds, while the cross-licence element survives.
Watch: A formal blocking order or conditional ruling
Probabilities are calibrated judgement based on the sources, not measurement, and are revised as new information arrives. Not investment advice.
Market reaction
Indicators affected
- Huawei cumulative licensing value▲ ≈$7bn
- Huawei valid patents (end-2025)▲ 165,000+
- Regulatory approval for patent sale▼ pending